TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

6A.6 Del Rosso JQ et al. A review of the anti-inflammatory properties of clindamycin in the treatment of acne
vulgaris. Cutis 2010;85:15-24.
6A.7 Schöfer H et al. Fusidic acid in dermatology: an updated review. Eur J Dermatol 2010;20:6-15.
6A.8 Korting HC et al. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol
Venereol 2009;23:876-82.
6A.9 Patel JB et al. Mupirocin resistance. Clin Infect Dis 2009;49:935-41.
6A.10 European Medeines Agency (EMA). European assessment report (EPAR). Altargo TM , summary of
product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR
_-_Product_Information/human/000757/WC500024409.pdf. Accessed on August 4th 2010.
6A.11 Scangarella-Oman NE et al. Microbiological profile of a new topical antibacterial: retapamulin ointment
1%. Expert Rev Anti Infect Ther 2009;7:269-79.
6A.12 Woodford N et al. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to
fusidic acid and mupirocin. J Antimicrob Chemother 2008;62:766-8.
6C.1 Liesegang TJ. Bacterial keratitis. Infect Dis Clin North Am 1992;6:815-29.
7.1 Nucci M et al. Emerging fungi. Infect Dis Clin North Am 2006;20:563-79.
7.2 Nucci M et al. Emerging fungal diseases. Clin Infect Dis 2005;41:521-6.
7.3 Pfaller MA et al. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43
(suppl. 1):S3-14.
7.4 De Pauw B et al. Revised definitions of invasive fungal disease from the European Organization for
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group.
Clin Infect Dis 2008;46:1813-21.
7.5 Alexander BD et al. Contemporary tools for the diagnosis and management of invasive mycoses. Clin
Infect Dis 2006;43(suppl. 1):S15-27.
7.6 Lass-Flörl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy.
Expert Rev Anti Infect Ther 2010;8:127-35.
7.7 Mukherjee PK et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005;
18:163-94.
7.8 Nivoix Y et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive
fungal infections. J Infect 2006;52:67-74.
7.9 Bille J et al. Changing face of health care associated fungal infections. Curr Opin Infect Dis 2005;
18:314-9.
7.10 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic
infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1-
207.
7.11 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of
opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009;
58(RR-11):1-167.
7.12 Revankar SG. Therapy for infections caused by dematiaceous fungi. Expert Rev Anti Infect Ther
2005;3:601-12.
7.13 Nucci M et al. When primary antifungal therapy fails. Clin Infect Dis 2008;46:1426-33.
7.14 Cordonnier C et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic
patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51.
7.15 de Pauw BE et al. Timely intervention for invasive fungal disease: should the road now lead to the laboratory
instead of the pharmacy? Clin Infect Dis 2009;48:1052-4.
7.16 Segal BH. Aspergillosis. N Engl J Med 2009;360:1870-84.
7.17 Singh N et al. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44-69.
7.18 Barnes PD et al. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North
Am 2006;20:545-61.
7.19 Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society
of America. Clin Infect Dis 2008;46:327-60.
7.20 Pasqualotto AC et al. Post-operative aspergillosis. Clin Microbiol Infect 2006;12:1060-76.
7.21 Hassoun A. Cauliflower mass obstructing the left main-stem bronchus. Clin Infect Dis 2008;47:585-
6.
7.22 Gibson PG. Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006;27:185-91.
7.23 Shoseyov D et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006;130:222-6.
7.24 Tillie-Leblond I et al. Allergic bronchopulmonary aspergillosis. Allergy 2005;60:1004-13.
7.25 Stevens DA et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. State of the art: Cystic
Fibrosis Foundation consensus conference. Clin Infect Dis 2003;37(suppl. 3):S225-64.
7.26 Stevens DA et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N
Engl J Med 2000;342:756-62.
7.27 Marple BF. Allergic fungal rhinosinusitis: current theories and management strategies.
Laryngoscope 2001;111:1006-19.
7.28 Sohail MA et al. Allergic fungal sinusistis: can we predict the recurrence? Otolaryngol Head Neck
Surg 2004;131:704-10.
7.29 Ebbens FA et al. Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis.
J Allergy Clin Immunol 2006;118:1149-56.
7.30 Kim YT et al. Good long-term outcomes after surgical treatment of simple and complex pulmonary
aspergilloma. Ann Thorac Surg 2005;79:294-8.
7.31 Okubo K et al. Favorable acute and long-term outcomes after the resection of pulmonary aspergillomas.
Thorac Cardiovasc Surg 2007;55:108-11.
7.32 Chatzimichalis A et al. Bronchopulmonary aspergilloma: a reappraisal. Ann Thorac Surg 1998;65:
927-9.
7.33 Maertens J et al. New therapies for fungal pneumonia. Curr Opin Infect Dis 2009;22:183-90.
7.34 Segal BH et al. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir
Crit Care Med 2006;173:707-17.
7.35 Doffman SR et al. Invasive pulmonary aspergillosis. Expert Rev Anti Infect Ther 2005;3:613-27.
7.36 Ruhncke M et al. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007;21:
659-76.
7.37 Ader F et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging
fungal pathogen. Clin Microbiol Infect 2005;11:427-9.